NEW YORK (GenomeWeb News) – The National Institutes of Health has made available for licensing miRNA technology that could be used to develop a diagnostic or a therapeutic for cervical cancer tumors related to cases of human papillomavirus.
The NIH also said it is seeking statements of capability or interest from parties who may wish to engage in collaborative research to develop, evaluate, or commercialize the p53 specific miR-34, which it said is downregulated in HPV-infected primary keratinocytes. The miR-34 has been shown to arrest the cell cycle at a certain phase in tumor development and to promote apoptosis.
Information about the miRNA technology was published in 2007 in the July issue of Cancer Research and the Nov. 12 edition of Oncogene.
The miRNA technology’s provisional application, number 60/983,368, was filed in October 2007, and its reference number is E-029-2008/0-US-01.